None listed
Conditions
Brief summary
This study aims to investigate how quickly two potent anitbiotics used to treat septic patients in the ICU are removed by haemodiafiltration (HDF). Septic patients often have acute kidney injury and require HDF support to maintain kidney function. We do not know how well antibiotics are removed by HDF and therefore do not have appropriate dosing guidelines to ensure adequate therapeutic concentrations of the antibiotic is maintained. This study will measure the changes in antibiotic concentrations over a HDF session. The results will enable us to more accurately recommend the correct dose and timing for the dose for septic patients with acute kidney injury.
Interventions
The pharmacokinetic study relates to a single HDF session, where the antibiotic (meropenem or tazocin) will be administered intravenously at 30 minutes prior to the start of the dialysis session. Basline bloods are taken. The anitbiotic is administered followed by a 15 and 30 minute sample. The dialysis session is then started and samples are then taken (15 min, 30 min, 60 min, 2 hours and 4 hours) to measure antibiotic concentrations over time during the 4 hour dialysis session followed by a p
The pharmacokinetic study relates to a single HDF session, where the antibiotic (meropenem or tazocin) will be administered intravenously at 30 minutes prior to the start of the dialysis session. Basline bloods are taken. The anitbiotic is administered followed by a 15 and 30 minute sample. The dialysis session is then started and samples are then taken (15 min, 30 min, 60 min, 2 hours and 4 hours) to measure antibiotic concentrations over time during the 4 hour dialysis session followed by a post dialysis sample 1 hour after completion.. Dose of Meropenem is 1gm IV (session 1) Dose of tazocin 4.5gms IV (session 2). Each participant will undergo 2 pharmacokinetic clearance studies on HDF. One for meropenem pharmacokinetics and one for Tazocin pharmacokinetics These studies will be separated by at least a week.
Sponsors
University of Otago
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Stable haemodialysis patients aged from 18 - 75 years. able to give informed consent.
Exclusion criteria
Unable to give consent. Known penicillin allergy or previous allergy to meropenem or tazocin. An intercurrent infection requiring antibiotic therapy.
Outcome results
None listed